The BA.3.2 variant, dubbed the “Cicada,” is a descendent of the BA.3 omicron subvariant that emerged in 2022. First identified in South Africa in November 2024, this variant is now making headlines as it spreads to over 20 countries, including 25 states in the United States.

Cicada carries approximately 70 to 75 mutations in its spike protein, raising concerns about its transmissibility. However, health experts emphasize that current evidence suggests BA.3.2 does not lead to more severe illness compared to earlier variants. Dr. Adolfo García-Sastre stated, “There’s no evidence that BA.3.2 is causing more severe disease or hospitalizations in countries where it’s more widespread.”

Common symptoms associated with the Cicada variant include cough, fever or chills, sore throat, congestion, shortness of breath, loss of smell or taste, fatigue, headache, and gastrointestinal issues like diarrhea or vomiting. Most cases appear mild to moderate, resembling flu-like illness, especially among vaccinated individuals.

Despite the variant’s mutations, vaccines are expected to provide strong protection against severe disease, even if breakthrough infections occur. Health authorities are actively monitoring the BA.3.2 variant due to its rising presence, urging the public to stay up to date with vaccinations and take precautions in crowded settings.

Health experts have noted that symptoms of the BA.3.2 Cicada variant are largely similar to earlier Omicron strains, with no new or unusual signs reported so far. “Most cases remain mild and can be managed at home with rest and hydration,” they advise.

While the current COVID-19 vaccines may not be as effective against it due to the multiple mutations, the overall risk remains manageable. Observers are keeping a close eye on the variant’s spread and its impact on public health.

As the Cicada variant continues to rise, health officials stress the importance of vigilance. With the variant primarily spreading through respiratory droplets and close contact in crowded or poorly ventilated spaces, precautions are crucial to mitigate its impact.

Details remain unconfirmed, but the consensus among health experts is clear: stay informed, stay vaccinated, and take necessary precautions to protect yourself and others.

The post Cicada COVID Variant Symptoms: What You Need to Know appeared first on India News.

The Cicada COVID-19 variant, an offshoot of the Omicron family, has emerged as a new concern in India. First spotted in South Africa in November 2024, it carries over 70 mutations compared to the original Wuhan strain, with around 50 of those located in the spike protein.

As of now, the variant has been detected in 22 countries, including India, where health officials are closely monitoring its spread. Symptoms associated with the Cicada variant include cough, extreme fatigue, runny nose, headache, sore throat, mild fever, muscle and joint pain, loss of taste or smell, night sweats, and rash.

Despite its extensive mutations, the Cicada variant is not confirmed to cause more severe illness than previous variants. This has led to some cautious optimism among health experts, though the situation remains fluid.

Dr. Robert Hopkins Jr. noted, “It is possible we will see Cicada become the dominant strain in the U.S., but that is by no means certain.” This statement underscores the uncertainty surrounding the variant’s potential impact.

The first confirmed case of the Cicada variant in the United States was reported in June 2025, with three patients confirmed by January 2026, all of whom recovered. This timeline highlights the variant’s rapid spread across borders.

Monitoring the spread of BA.3.2, as the Cicada variant is classified, is crucial. The CDC emphasized that it provides valuable information about the potential for this new SARS-CoV-2 lineage to evade immunity from previous infections or vaccinations.

Details remain unconfirmed regarding the real-world data on the severity of illness caused by the Cicada variant. As health officials in India and around the world continue to assess the situation, the focus remains on understanding the implications of this new variant.

As the pandemic evolves, the emergence of the Cicada variant serves as a reminder of the ongoing challenges posed by COVID-19. Vigilance and adaptability in public health responses will be essential in managing its spread.

The post Cicada COVID Variant in India Raises Concerns appeared first on India News.